Multi-tyrosine kinase inhibitors (MTKIs) have thus far had limited success in the treatment of
castration-resistant prostate cancer (CRPC). Here, we report a phase I–cleared orally …

Context Androgen deprivation therapy (ADT) is the backbone of treatment for advanced
prostate cancer. However, castration-resistant prostate cancer (CRPC) nearly invariably …

Abstract Purpose of Review Compensatory mechanisms leading to increased androgen
receptor expression and activity after androgen ablation or anti-androgen treatment have …

Purpose: Lineage plasticity in prostate cancer—most commonly exemplified by loss of
androgen receptor (AR) signaling and a switch from a luminal to alternate differentiation …

Identification oncogenes is fundamental to revealing the molecular basis of cancer. Here, we
found that FOXP2 is overexpressed in human prostate cancer cells and prostate tumors, but …

Cabozantinib (XL-184) is a multitarget tyrosine kinase inhibitor (TKI) targeting receptor
tyrosine kinases (RTKs) involved in oncogenesis and angiogenesis. It is currently the …

Prostate cancer (PCa) is the second most prevalent malignancy in males across the world. A
greater knowledge of the relationship between protein abundance and drug responses …

Androgen deprivation therapy (ADT) targeting androgen/androgen receptor (AR)-signaling
pathways is the main therapy for advanced prostate cancer (PCa). However, ADT eventually …

Castration-resistant prostate cancer (CRPC), the invariably lethal phenotype of advanced
prostate cancer, represents a clinical state defined by disease progression despite reduction …

Up to 30% of patients with metastatic castration‐resistant prostate cancer (CRPC) patients
carry altered DNA damage response genes, enabling the use of poly adenosine …